Overview
VRDN market data
Price History
VRDN price chart · 1M
- O
- 23.98
- H
- 24.25
- L
- 23.82
- C
- 23.89
- Vol
- 67,074.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $23.98
- Previous Close
- $24.26
- Day High
- $24.25
- Day Low
- $23.82
- 52 Week High
- $24.85
- 52 Week Low
- $13.18
- 7 Day Return
- -2.53%
- 30 Day Return
- +22.45%
- 90 Day Return
- +35.55%
- 1 Year Return
- +79.62%
- Daily Notional Volume
- $1.6M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -544.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.18 – $34.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 4.11 · P/S 34.80.
Company News
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36Benzinga · Aug 7, 2026, 8:25 PM
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39Benzinga · Aug 7, 2026, 1:27 PM
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.Benzinga · Aug 6, 2026, 7:50 PM
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K EstimateBenzinga · Aug 6, 2026, 11:50 AM
8-K filing — Viridian Therapeutics, Inc.\DE (VRDN)SEC EDGAR · Aug 6, 2026, 11:05 AM
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35Benzinga · Jun 30, 2026, 3:40 PM
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38Benzinga · Jun 30, 2026, 2:00 PM
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43Benzinga · Jun 30, 2026, 12:50 PM
Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31Benzinga · Jun 29, 2026, 5:00 PM
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye DiseaseBenzinga · Jun 29, 2026, 1:25 PM